Home  |  Contact

Cellosaurus CCRF-CEM (CVCL_0207)

Cell line name CCRF-CEM
Synonyms CCRF/CEM; CCRFCEM; CCRF.CEM; CCRF CEM; CCRF; CEM; CEM-CCRF; CEM-CCRF (CAMR); CCRF/CEM/0; CEM/0; CEM-0; CCRF-CEM/S; GM03671
Accession CVCL_0207
Resource Identification Initiative To cite this cell line use: CCRF-CEM (RRID:CVCL_0207)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Part of: NCI-60 cancer cell line panel.
Part of: NCI-7 clinical proteomics reference material cell line panel.
Doubling time: 23 hours (PubMed=17117183); 24 hours (PubMed=20922763); 26.7 hours (NCI-DTP); ~24-30 hours (DSMZ).
Microsatellite instability: Instable (MSI-low) (Sanger).
Omics: Array-based CGH.
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: DNA methylation analysis.
Omics: Fluorescence phenotype profiling.
Omics: Metabolome analysis.
Omics: lncRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Proteome analysis by 2D-DE/MS.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Peripheral blood.
Sequence variations Heterozygous for FLT3 p.Ala627Thr (c.1879G>A) (PubMed=17088437).
Heterozygous for KRAS p.Gly12Asp (c.35G>A) (PubMed=17088437).
Heterozygous for TP53 p.Arg175His (c.524G>A) and p.Arg248Gln (c.743G>A) (PubMed=17088437).
HLA typing Source: PubMed=15748285
Class I
HLA-BB*08,40
HLA-CC*03:04:01,07
Class II
HLA-DPDPB1*04:01,13:01
HLA-DQDQB1*02:01,02:02
HLA-DRDRB1*03:01:01,07:01
Disease Childhood T acute lymphoblastic leukemia (NCIt: C7953)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_2265 (1301)CVCL_6869 (6T-CEM)CVCL_6244 (A3.01)
CVCL_D101 (AG-F)CVCL_GZ09 (ARAC-8C)CVCL_GZ10 (ARAC-8D)
CVCL_G691 (BUC)CVCL_6825 (CCRF-CEM C7)CVCL_V324 (CCRF-CEM R3/7)
CVCL_V323 (CCRF-CEM R30/6)CVCL_5H79 (CCRF-CEM/HU-R)CVCL_5H80 (CCRF-CEM/MTX R1)
CVCL_5H81 (CCRF-CEM/MTX R2)CVCL_5H82 (CCRF-CEM/MTX R3)CVCL_5H83 (CCRF-CEM/MTX140-LV)
CVCL_5H84 (CCRF-CEM/MTX1500-LV)CVCL_5H85 (CCRF-CEM/MTX5000-PGA)CVCL_5H86 (CCRF-CEM/MTX60-PGA)
CVCL_S649 (CCRF-CEM/R1)CVCL_S651 (CCRF-CEM/R3)CVCL_D545 (CCRF/ACTD400)
CVCL_D544 (CCRF/ADR5000)CVCL_4V17 (CCRF/CEM/ara-C/3A)CVCL_4V18 (CCRF/CEM/ara-C/7A)
CVCL_D546 (CCRF/VCR1000)CVCL_V186 (CEM cl13)CVCL_J396 (CEM-AGR)
CVCL_X635 (CEM-CL10)CVCL_3930 (CEM-CM3)CVCL_1G53 (CEM-GFP)
CVCL_3931 (CEM-LAV-2)CVCL_HF38 (CEM-R6)CVCL_J318 (CEM-SS)
CVCL_8178 (CEM-T4)CVCL_X697 (CEM-TART)CVCL_D598 (CEM-VBL16)
CVCL_3933 (CEM-VCR R)CVCL_4V08 (CEM-VLB)CVCL_X622 (CEM.NKR)
CVCL_U260 (CEM/A5)CVCL_U261 (CEM/A7)CVCL_4V21 (CEM/ara-C)
CVCL_3496 (CEM/C1)CVCL_3497 (CEM/C2)CVCL_S256 (CEM/DNR)
CVCL_0U11 (CEM/MX1)CVCL_D597 (CEM/VLB10)CVCL_3932 (CEM/VLB100)
CVCL_4V12 (CEM/VLB500)CVCL_4V09 (CEM/VLB55)CVCL_1B35 (CEM/VM-1)
CVCL_7905 (CEMR.3)CVCL_J653 (CO)CVCL_8865 (EU-7)
CVCL_8265 (MKB-1)CVCL_L808 (RC-2A)CVCL_GZ11 (TUB-4D)
CVCL_8276 (UTMB-460)CVCL_A036 (WSU-ALCL)
Sex of cell Female
Age at sampling 3Y11M
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CLS; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; PubMed=19372543; PubMed=20922763; RCB

Markers:
AmelogeninX
CSF1PO10,11 (AddexBio; ATCC_CCL-119; Cosmic-CLP; JCRB_IFO50412_JCRB9023; KCLB; PubMed=20922763)
10,13 (ATCC_CRL-8436; CLS; DSMZ)
11 (ECACC; JCRB_JCRB0033; PubMed=19372543)
9,10,11 (RCB)
D13S31711,12 (AddexBio; ATCC_CCL-119; Cosmic-CLP; ECACC; JCRB; KCLB; PubMed=19372543; PubMed=20922763)
11 (ATCC_CRL-8436; CLS; DSMZ)
10,11,12 (RCB)
D16S53910,13 (AddexBio; ATCC_CCL-119; ATCC_CRL-8436; CLS; Cosmic-CLP; DSMZ; ECACC; JCRB; PubMed=19372543; PubMed=20922763)
10,13,14 (RCB)
D18S5113,18
D19S43314,15
D21S1130,33.2,34.2 (CLS)
30,33.2 (PubMed=19372543; PubMed=20922763)
D2S133824
D3S135814,15,16 (CLS)
14,15 (KCLB)
15 (PubMed=19372543)
15,16 (PubMed=20922763)
D5S81812,13 (AddexBio; ATCC_CCL-119; ATCC_CRL-8436; CLS; DSMZ; ECACC; KCLB; PubMed=19372543; PubMed=20922763; RCB)
12,13,14 (Cosmic-CLP)
D7S8209,13 (AddexBio; ATCC_CCL-119; ATCC_CRL-8436; CLS; Cosmic-CLP; DSMZ; ECACC; JCRB_IFO50412_JCRB9023; KCLB; PubMed=19372543; PubMed=20922763; RCB)
9,12 (JCRB_JCRB0033)
D8S117912,13 (CLS; PubMed=20922763)
13 (PubMed=19372543)
FGA23,24,25 (CLS)
23,24 (PubMed=19372543; PubMed=20922763)
Penta D10,11
Penta E5,14
TH016,7
TPOX8 (AddexBio; ATCC_CCL-119; ATCC_CRL-8436; Cosmic-CLP; ECACC; JCRB; KCLB; RCB; PubMed=19372543; PubMed=20922763)
7,8 (CLS; DSMZ)
vWA17,19 (AddexBio; ATCC_CCL-119; ATCC_CRL-8436; Cosmic-CLP; DSMZ; ECACC; JCRB; KCLB; PubMed=19372543; PubMed=20922763)
17,18,19,20 (CLS)
18,19 (RCB)
Web pages https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
https://strap.nci.nih.gov/celline_detail.php?sample_id=29
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/c/cell-lines-detail-12.html
http://www.cogcell.org/cellreqs-ncipptp.php
http://www.pptpinvitro.org/cell_lines_panel.php
http://www.nibsc.org/Default.aspx?pageid=597&id=0005&theme=default
http://tcpaportal.org/mclp/
Publications

PubMed=14278051; DOI=10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J
Foley G.E., Lazarus H., Farber S., Uzman B.G., Boone B.A., McCarthy R.E.
Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia.
Cancer 18:522-529(1965)

PubMed=5224274; DOI=10.1002/1097-0142(196611)19:11<1725::AID-CNCR2820191142>3.0.CO;2-T
Uzman B.G., Foley G.E., Farber S., Lazarus H.
Morphologic variations in human leukemic lymphoblasts (CCRF-CEM cells) after long-term culture and exposure to chemotherapeutic agents. A study with the electron microscope.
Cancer 19:1725-1742(1966)

PubMed=6600440; DOI=10.1007/BF02617996
Uittenbogaart C.H., Cantor Y., Fahey J.L.
Growth of human malignant lymphoid cell lines in serum-free medium.
In Vitro 19:67-72(1983)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3495441; DOI=10.1002/eji.1830170503
Kanowith-Klein S., Saxon A., Uittenbogaart C.H.
Constitutive production of B cell differentiation factor-like activity by human T and B cell lines.
Eur. J. Immunol. 17:593-598(1987)

PubMed=2041050; DOI=10.1093/jnci/83.11.757
Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M.
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
J. Natl. Cancer Inst. 83:757-766(1991)

PubMed=8127147
Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y., Xu B., Einhorn S.
Interferon system defects in malignant T-cells.
Leukemia 8:425-434(1994)

PubMed=7630190
Zhou M., Gu L., James C.D., He J., Yeager A.M., Smith S.D., Findley H.W.
Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia.
Leukemia 9:1159-1161(1995)

PubMed=7888679
Zhou M., Yeager A.M., Smith S.D., Findley H.W.
Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.
Blood 85:1608-1614(1995)

PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x
Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G., Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.
Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines.
Br. J. Haematol. 91:350-354(1995)

PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x
Borgonovo Brandter L., Heyman M., Rasool O., Liu Y., Grander D., Einhorn S.
p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines.
Eur. J. Haematol. 56:313-318(1996)

PubMed=9108419
Findley H.W., Gu L., Yeager A.M., Zhou M.
Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia.
Blood 89:2986-2993(1997)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=9557624; DOI=10.1038/sj.leu.2400976
Mattii L., Barale R., Petrini M.
Use of the comet test in the evaluation of multidrug resistance of human cell lines.
Leukemia 12:627-632(1998)

PubMed=9685479; DOI=10.1093/nar/26.16.3651
Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T., Roos G.
Telomere analysis by fluorescence in situ hybridization and flow cytometry.
Nucleic Acids Res. 26:3651-3656(1998)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)

PubMed=9823951; DOI=10.1038/sj.leu.2401198
Zhou M., Gu L., Yeager A.M., Findley H.W.
Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression.
Leukemia 12:1756-1763(1998)

PubMed=9933131; DOI=10.1016/S0145-2126(98)00133-7
Burger R., Hansen-Hagge T.E., Drexler H.G., Gramatzki M.
Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines: suggestion for classification by immunophenotype and T-cell receptor studies.
Leuk. Res. 23:19-27(1999)

PubMed=10071127; DOI=10.1016/S0145-2126(98)00146-5
Kawamura M., Ohnishi H., Guo S.X., Sheng X.M., Minegishi M., Hanada R., Horibe K., Hongo T., Kaneko Y., Bessho F., Yanagisawa M., Sekiya T., Hayashi Y.
Alterations of the p53, p21, p16, p15 and RAS genes in childhood T-cell acute lymphoblastic leukemia.
Leuk. Res. 23:115-126(1999)

PubMed=10700174; DOI=10.1038/73432
Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P., Iyer V., Jeffrey S.S., Van de Rijn M., Waltham M., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.
Systematic variation in gene expression patterns in human cancer cell lines.
Nat. Genet. 24:227-235(2000)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

CLPUB00158
Anagnostopoulos A.K., Vougas K., Kolialexi A., Mavrou A., Fountoulakis M., Tsangaris G.M.
The protein profile of the human immature T-cell line CCRF-CEM.
Cancer Genomics Proteomics 2:271-299(2005)

PubMed=15748285; DOI=10.1186/1479-5876-3-11
Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. III, Stroncek D., Marincola F.M.
HLA class I and II genotype of the NCI-60 cell lines.
J. Transl. Med. 3:11-11(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433
Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17117183; DOI=10.1038/sj.bjc.6603447
Beesley A.H., Palmer M.-L., Ford J., Weller R.E., Cummings A.J., Freitas J.R., Firth M.J., Perera K.U., de Klerk N.H., Kees U.R.
Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.
Br. J. Cancer 95:1537-1544(2006)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921
Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.
DNA fingerprinting of the NCI-60 cell line panel.
Mol. Cancer Ther. 8:713-724(2009)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=22384151; DOI=10.1371/journal.pone.0032096
Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
PLoS ONE 7:E32096-E32096(2012)

PubMed=22675565; DOI=10.1371/journal.pone.0038463
Kalender Atak Z., De Keersmaecker K., Gianfelici V., Geerdens E., Vandepoel R., Pauwels D., Porcu M., Lahortiga I., Brys V., Dirks W.G., Quentmeier H., Cloos J., Cuppens H., Uyttebroeck A., Vandenberghe P., Cools J., Aerts S.
High accuracy mutation detection in leukemia on a selected panel of cancer genes.
PLoS ONE 7:E38463-E38463(2012)

PubMed=22628656; DOI=10.1126/science.1218595
Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336:1040-1044(2012)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342
Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L., Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018
Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M., Kuster B.
Global proteome analysis of the NCI-60 cell line panel.
Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20
Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Cancer Metab. 1:20-20(2013)

PubMed=24670534; DOI=10.1371/journal.pone.0092047
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
PLoS ONE 9:E92047-E92047(2014)

PubMed=27377824; DOI=10.1038/sdata.2016.52
Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4
Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Mob. DNA 7:20-20(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29718670; DOI=10.1021/acs.jproteome.8b00165
Clark D.J., Hu Y., Bocik W., Chen L., Schnaubelt M., Roberts R., Shah P., Whiteley G., Zhang H.
Evaluation of NCI-7 cell line panel as a reference material for clinical proteomics.
J. Proteome Res. 18:2205-2215(2018)

Cross-references
Cell line collections AddexBio; C0003001/32
ATCC; CCL-119
ATCC; CRM-CCL-119
ATCC; CRL-7916 - Discontinued
ATCC; CRL-8436
BCRC; 60137
BCRJ; 0063
CLS; 300147/p752_CCRF-CEM
Coriell; GM03671
DSMZ; ACC-240
ECACC; 85112105
IZSLER; BS TCL 11
JCRB; IFO50412
JCRB; JCRB0033
JCRB; JCRB9023
KCLB; 10119
NCBI_Iran; C105
NCI-DTP; CCRF-CEM
RCB; RCB1980
TKG; TKG 0563
Cell line databases/resources CLDB; cl675
CLDB; cl676
CLDB; cl677
CCLE; CCRFCEM_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
CCRID; 3131C0001000700129
CCRID; 3131C0001000700147
Cosmic-CLP; 905952
GDSC; 905952
IGRhCellID; CCRFCEM
IMGT/HLA; 10403
LINCS_LDP; LCL-1012
Lonza; 647
SKY/M-FISH/CGH; 2784
Ontologies BTO; BTO:0000736
CLO; CLO_0002334
CLO; CLO_0015478
CLO; CLO_0050143
EFO; EFO_0002128
MCCL; MCC:0000096
MCCL; MCC:0000097
Biological sample resources BioSample; SAMN01821675
BioSample; SAMN03471121
BioSample; SAMN03471203
BioSample; SAMN03472050
BioSample; SAMN03472700
BioSample; SAMN03472808
BioSample; SAMN03473385
Chemistry resources ChEMBL-Cells; CHEMBL3307510
ChEMBL-Cells; CHEMBL3307641
ChEMBL-Targets; CHEMBL382
ChEMBL-Targets; CHEMBL393
ChEMBL-Targets; CHEMBL614028
Gene expression databases ArrayExpress; E-MTAB-3610
GEO; GSM2116
GEO; GSM50193
GEO; GSM50257
GEO; GSM236780
GEO; GSM236816
GEO; GSM750806
GEO; GSM799345
GEO; GSM799408
GEO; GSM1153416
GEO; GSM1181330
GEO; GSM1181347
GEO; GSM1374445
GEO; GSM1669670
GEO; GSM2124653
Other Wikidata; Q54809015
Polymorphism and mutation databases Cosmic; 683716
Cosmic; 721708
Cosmic; 801728
Cosmic; 846384
Cosmic; 850198
Cosmic; 875863
Cosmic; 897449
Cosmic; 905952
Cosmic; 913411
Cosmic; 919157
Cosmic; 922674
Cosmic; 932765
Cosmic; 933544
Cosmic; 974251
Cosmic; 1012060
Cosmic; 1037690
Cosmic; 1044252
Cosmic; 1070703
Cosmic; 1071876
Cosmic; 1092595
Cosmic; 1115588
Cosmic; 1118462
Cosmic; 1127261
Cosmic; 1151774
Cosmic; 1175854
Cosmic; 1176599
Cosmic; 1191691
Cosmic; 1224367
Cosmic; 1226857
Cosmic; 1247870
Cosmic; 1281365
Cosmic; 1305336
Cosmic; 1330503
Cosmic; 1375587
Cosmic; 1483363
Cosmic; 1509201
Cosmic; 1523831
Cosmic; 1524793
Cosmic; 1639635
Cosmic; 1664520
Cosmic; 1760519
Cosmic; 1998437
Cosmic; 2165706
Cosmic; 2301560
Cosmic; 2361364
Cosmic; 2433754
Cosmic; 2458763
Cosmic; 2462863
Cosmic; 2602911
Cosmic; 2649235
Cosmic; 2649237
Cosmic; 2668294
Proteomic databases PRIDE; PXD005940
PRIDE; PXD005942